[1] SUN M, QIAN Q, SHI L, et al. Amphiphilic drug-drug conjugate for cancer therapy with combination of chemotherapeutic and antiangiogenesis drugs[J]. Sci China Chem(中国科学 化学), 2020, 63(1):35-41.
[2] KUMSTEL S, VASUDEVAN P, PALME R, et al. Benefits of non-invasive methods compared to telemetry for distress analysis in a murine model of pancreatic cancer[J]. J Adv Res, 2020, 21:35-47.
[3] LIANG B, ZHAO D, LIU Y, et al. Chemoembolization of liver cancer with doxorubicin-loaded Calli Spheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model[J]. Drug Deliv Transll Res, 2020, 10(1):185-191.
[4] GOOS J A C M, CHO A, CARTER L M, et al. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect[J]. Theranostics, 2020, 10(2):567-584.
[5] FERREIRA L L, CERVANTES M, FROUFE H J C, et al. Doxorubicin persistently rewires cardiac circadian homeostasis in mice[J]. Arch Toxicol, 2020, 94(1):257-271.
[6] PUTTHIKORN S, RUENGROT P, BAOWAN D. Energy behaviour of doxorubicin interacting with peptide nanotubes[J]. J Math Chem, 2020, 58(2):382-392.
[7] DARRELL J I, ERIC L D. Enhancing cancer immunotherapy with nanomedicine[J]. Nat Rev Immunol, 2020, 20(5):321-334.
[8] SHENGPING Z, DIAN W, JINGYING H, et al. Application of capsaicin as a potential new therapeutic drug in human cancers[J]. J Clin Pharm Ther, 2019,45(8):1-13.
[9] MARTIN J D, CABRAL H, STYLIANOPOULOS T, et al. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges[J]. Nat Rev Clin Oncol, 2020, 17(4):251-266.
[10] KAMALY N, YAMEEN B, WU J, et al. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release[J]. Chem Rev, 2016, 116(4):2602-2663.
[11] BOBO D, ROBINSON K J, ISLAM J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date[J]. Pharm Res, 2016, 33(10):2373-2387.
[12] BLANCO E, SHEN H, FERRARI M. Principles of nanoparticle design for overcoming biological barriers to drug delivery[J]. Nat Biotechnol, 2015, 33(9):941-951.
[13] YAN D, LEI B, CHEN B, et al. Synthesis of high-quality lanthanide oxybromides nanocrystals with single-source precursor for promising applications in cancer cells imaging[J]. Appl Mater Today, 2015, 1(1):20-26.
[14] BI D, ZHAO L, ZHAO X, et al. Preparation of polydopamine-based hydroxycamptothecin nanocrystals for potential osteosarcoma treatment[J]. Chin J New Drugs(中国新药杂志),2018, 27(13):1549-1554.
[15] ZHANG C, ZHANG S, ZHI D, et al. Co-delivery of paclitaxel and survivin siRNA with cationic liposome for lung cancer therapy[J]. Colloids Surfaces A-Physicochem Eng Aspec, 2020,585:124054.
[16] HUANG Z G, LV F M, WANG J, et al. RGD-modified PEGylated paclitaxel nanocrystals with enhanced stability and tumor-targeting capability[J]. Int J Pharm, 2019, 556:217-225.
[17] LOW L E, TAN L T H, GOH B H, et al. Magnetic cellulose nanocrystal stabilized pickering emulsions for enhanced bioactive release and human colon cancer therapy[J]. Int J Biol Macromol, 2019, 127:76-84.
[18] CHEN J, MAO L, QI H, et al. Preparation of fluorescent cellulose nanocrystal polymer composites with thermo-responsiveness through light-induced ATRP[J]. Cellulose, 2020, 27(2):743-753.
[19] NA L. Rod-like cellulose nanocrystals are acid-sensitive nanomedicines[D]. East China Normal University, 2019.
[20] BENJAMIN R, CHRISTELLE P, GAUTIER M A N N, et al. Enhancement of hydrosolubility and in vitro antiproliferative properties of chalcones following encapsulation into β-cyclodextrin/cellulose-nanocrystal complexes[J]. Bioorg Med Chem Lett, 2019, 29(15):1895-1898.
[21] SHIEKHZADEH A, SOHRABI N, MOGHADAM M E, et al. Kinetic and thermodynamic investigation of human serum albumin interaction with anticancer glycine derivative of platinum complex by using spectroscopic methods and molecular docking[J]. Appl Biochem Biotechnol, 2020, 190(2):506-528.
[22] PARK J, SUN B, YEO Y. Albumin-coated nanocrystals for carrier-free delivery of paclitaxel[J]. J Controlled Release, 2017, 263:90-101.
[23] PARK J E, PARK J, JUN Y, et al. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation[J]. J Controlled Release, 2019, 302:148-159.
[24] LIU J, TU L, CHENG M, et al. Mechanisms for oral absorption enhancement of drugs by nanocrystals[J]. J Drug Deliv Sci Technol, 2020, 56:101607.
[25] IMONO M, UCHIYAMA H, YOSHIDA S, et al. The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: in vitro-in vivo correlation of nanocrystals[J]. Eur J Pharm Biopharm, 2020, 146:84-92.
[26] YUEQIN M A, ZHANG Z Z, GANG L I, et al. Advances in nanocrystal technology and its application in targeted drug delivery[J]. Chin J Hosp Pharm(中国医院药学杂志), 2018, 38(9):1014-1017.
[27] YU X, SUN L, TAN L, et al. Preparation and characterization of PLGA-PEG-PLGA nanoparticles containing salidroside and tamoxifen for breast cancer therapy[J]. AAPS Pharm Sci Tech, 2020, 21(3):85-96.
[28] SIBI R, SARTAJ K, RAMESH C, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy[J]. Semin Cancer Biol, 2019,11(9):523-537.
[29] KHAN H, MIRZAEI H R, AMIRI A, et al. Glyco-nanoparticles: new drug delivery systems in cancer therapy[J]. Semin Cancer Biol, 2019,12(4):276-295.
[30] HAN Y, HU B, WANG M, et al. pH-Sensitive tumor-targeted hyperbranched system based on glycogen nanoparticles for liver cancer therapy[J]. Appl Mater Today, 2020,18:100521.
[31] LI R, HE Y, ZHANG S, et al. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment[J]. Acta Pharm Sin B(药学学报英文), 2018, 8(1):14-22.
[32] HUANG J W, JIANG C Y, LUO Y Y, et al. A novel drug delivery system—red blood cell membranes biomimetic nanoparticles[J]. J Sun Yat-sen Univ Nat Sci Ed(中山大学学报 自然科学版), 2019, 58(5):114-118.
[33] KAN X B. Shanghai Institute of Materia Medica, Chinese Academy of Sciences discovered that tumor-selective bionic nanoparticles can inhibit breast cancer in situ tumor growth and lung metastasis[J]. Cap Food Med(首都食品与医药),2018,25(8):5
[34] LIU C M, CHEN G B, CHEN H H, et al. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment[J]. Colloids Surfaces B-Biointerfaces, 2019, 175:477-486.
[35] JIANG Q, LIU Y, GUO R, et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors[J]. Biomaterials, 2019, 192:292-308.
[36] XIA Y, XIA Q, CUI H, et al. Homologous membrane coated intelligent drug release nanoparticles for targeted therapy of liver cancer[J]. Appl Chem, 2020, 37(1):69-79.
[37] YANG R, XU J, XU L, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination[J]. Acs Nano, 2018, 12(6):5121-5129.
[38] XIA Q, ZHANG Y, LI Z, et al. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application[J]. Acta Pharm Sin B(药学学报英文), 2019, 9(4):675-689.
[39] XU C H, YE P J, ZHOU Y C, et al. Cell membrane-camouflaged nanoparticles as drug carriers for cancer therapy[J]. Acta Biomater, 2020, 105:1-14.
[40] LUK B T, ZHANG L. Cell membrane-camouflaged nanoparticles for drug delivery[J]. J Controlled Release, 2015, 220:S0168365915300328.
[41] CUI L, GUO T T, YU L. Research progress of different binding biomimetic nanoparticles[J]. Chin J Clin Pharmacol, 2018, 34(1):81-84.
[42] KANG T, KIM Y G, KIM D, et al. Inorganic nanoparticles with enzyme-mimetic activities for biomedical applications[J]. Coord Chem Rev, 2020, 403:213092.
[43] JANG E H, KIM G L, PARK M G, et al. Hypoxia-responsive, organic-inorganic hybrid mesoporous silica nanoparticles for triggered drug release[J]. J Drug Deliv Sci Technol, 2020, 56:101543.
[44] ELZOGHBY A O, HEMASA A L, FREAG M S. Hybrid protein-inorganic nanoparticles: from tumor-targeted drug delivery to cancer imaging[J]. J Controlled Release, 2016, 243:303-322.
[45] PUGAZHENDHI A, EDISON T N J I, KARUPPUSAMY I, et al. Inorganic nanoparticles: a potential cancer therapy for human welfare[J]. Int J Pharm, 2018, 539(1-2):104-111.
[46] GAO J L, GONG J B, LIU Y M, et al. Study on the modification of Fe₃O₄ nanoparticles with -cyclodextrin for drug delivery system[J]. Mod Chem Ind, 2019,40(2):157-161.
[47] NEHRU S, SAKTHINATHAN S, TAMIZHDURAI P, et al. Reduced graphene oxide/multiwalled carbon nanotube composite decorated with Fe₃O₄ magnetic nanoparticles for electrochemical determination of hydrazine in environmental water[J]. J Nanosci Nanotechnol, 2020, 20(5):3148-3156.
[48] DING Y, GUO H, GE W, et al. Copper(I) oxide nanoparticles catalyzed click chemistry based synthesis of melampomagnolide b-triazole conjugates and their anti-cancer activities[J]. Eur J Med Chem, 2018, 156:216-229.
[49] WU D, WANG W, HE X, et al. Biofabrication of nano copper oxide and its aptamer bioconjugate for delivery of mRNA 29b to lung cancer cells[J]. Mater Sci Eng C-Mater Biol Appl, 2019, 97:827-832.
[50] REN Q. Effect of Cuprous oxide nanoparticles (CONPs) on bladder urothelial carcinoma[D]. Shanghai:PLA Naval Medical University,2018.
[51] YU B. Inhibition and killing of human melanoma stem cells by Cuprous oxide nanoparticles (CONPs)[D]. Shanghai:Second Military Medical University,2016.
[52] XIA L. Treatment and mechanism of cuprous oxide nanoparticles for cervical cancer[D]. Shanghai: Second Military Medical University, 2017.
[53] KUMAR A, RATHI E, KINI S G. Drug repurposing approach for the identification and designing of potential E6 inhibitors against cervical cancer: an in silico investigation[J]. Struct Chem, 2020, 31(1):141-153.
[54] PIERETTI J C, ROLIM W R, FERREIRA F F, et al. Synthesis, characterization, and cytotoxicity of Fe₃O₄@Ag hybrid nanoparticles: promising applications in cancer treatment[J]. J Cluster Sci, 2020, 31(2):535-547.
[55] SUNDRARAMAN G, JAYAKUMARI L S. Meticulous taxifolin releasing performance by the zinc oxide nanoparticles: as a short road to drug delivery system for cancer therapeutics[J]. J Cluster Sci, 2020, 31(1):241-255.
[56] AHAMED M, AKHTAR M J, ALHADLAQ H A, et al. Copper ferrite nanoparticle-induced cytotoxicity and oxidative stress in human breast cancer MCF-7 cells[J]. Colloids Surfaces B-Biointerfaces, 2016, 142:46-54.
[57] HAMZELOU, JESSICA. DNA origami nanorobot takes drug direct to cancer cell[J]. New Sci, 2012, 213(2853):9.
[58] LI S, JIANG Q, DING B, et al. Anticancer activities of tumor-killing nanorobots[J]. Trends Biotechnol, 2019, 37(6):573-577.
[59] CHO H S, WOO T H. Conceptual design of nano-robotics for carrying the radioisotope material in nuclear industry[J]. Ann Nucl Energy, 2015, 80:429-433.
[60] "Intelligent DNA nanobots for cancer treatment" was selected as one of the top 10 scientific advances in China in 2018[J]. Cancer Res Prey Treat, 2019, 46(4):387.
[61] ZHANG Y L, LI S P, JIANG Q, et al. An intelligent DNA nanorobot for tumor vascular embolization therapy[J]. Chin Sci Bull, 2019, (25):2625-2632.
[62] SINGH H R, KOPPERGER E, SIMMEL F C. A DNA nanorobot uprises against cancer[J]. Trends Mol Med, 2018, 24(7):591-593.
[63] TRIPATHI R, KUMAR A. Application of nanorobotics for cancer treatment[J]. Maters Today Proc, 2018, 5(3):9114-9117.
[64] Nanobots developed by Chinese scientists are expected to be a new treatment for cancer[J]. Chin Cancer Clin Rehabil(中国肿瘤临床与康复), 2019,26(1):53.
[65] BALA, PRABHAKAR, PRAVIN, et al. Current trends and emerging diagnostic techniques for lung cancer[J]. Biomed Pharmacother, 2018,106:1586-1599.
[66] PENG T, DENG Z, HE J, et al. Functional nucleic acids for cancer theranostics[J]. Coord Chem Rev, 2020, 403:213080.
[67] PENG R, ZHENG X, LYU Y, et al. Engineering a 3D DNA-logic gate nanomachine for bispecific recognition and computing on target cell surfaces[J]. J Am Chem Soc, 2018, 140(31):9793-9796.
[68] MAHESWARI R, SHEEBA RANI S, GOMATHY V, et al. Cancer detecting nanobot using positron emission tomography[J]. Proc Comp Sci, 2018, 133:315-322.
[69] WANG X. Briefly description of the research progress of precision medicine in cancer treatment[J]. Rural Econom Sci Technol, 2017, 28(14):283.
[70] FENG L, DONG Z, LIANG C, et al. Iridium nanocrystals encapsulated liposomes as near-infrared light controllable nanozymes for enhanced cancer radiotherapy[J]. Biomaterials, 2018, 181:81-91.
[71] GAO F, WU J, GAO H, et al. Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics[J]. Biomaterials, 2020, 230:119635.
[72] FAN K, XI J, FAN L, et al. In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy[J]. Nat Commun, 2018, 9(1):1440-1440.
[73] ZENG L, HUANG K, WAN Y, et al. Programmed hunger and photodynamic synergetic cancer therapy[J]. Sci China Mater, 2019,15(12):1-9.
[74] WANG Z Q. Application of ferric phosphate REDOX nanase in tumor oxidative stress therapy[D]. Qingdao:Qingdao University of Science and Technology,2019.
[75] ZHANG L, WANG Z, ZHANG Y, et al. Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy[J]. Acs Nano, 2018, 12(10):10201-10211.
[76] CAO F. The design of a new generation of nanometer enzyme and its biological application[D]. Hefei: China Science & Technology University, 2019.
[77] JOLANTA K, BARTOSZ K, LESZEK K. Correction to: glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy[J]. Eur J Nucl Med Mol Imag, 2019, 47(2):886-887.
[78] MA X, REN X, GUO X,et al. Multifunctional iron-based metal-organic framework as biodegradable nanozyme for microwave enhancing dynamic therapy[J]. Biomaterials, 2019, 214:119223.
[79] XU Q. Design of biosensor based on nucleic acid probe and nanometer enzyme and its application in detection of cancer markers[D]. Wuhan: Huazhong University of Science and Technology, 2019.
[80] LI Z, SUN Y, QIAN Q J. Targeted immunotherapy may become a key strategy to cure cancer[J]. Chin J Cancer Biother(中国肿瘤生物治疗杂志), 2019, 26(1):13-21.
[81] HU X, XIA B, BAO Y,et al. Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies (vol 196, pg 172, 2020)[J]. Strahlenther Onkol,2020,196(4):405-405.